AMBALALSA vs SYMBIOTEC: Stock Comparison
SYMBIOTEC PHARMALAB is the larger company by market capitalisation. AMBALALSA shows a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AMBALALSA leads 1; SYMBIOTEC leads 0 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | AMBALALSA | SYMBIOTEC |
|---|---|---|
| Live Price | ₹47.74 | ₹1,038.6 |
| Day Change | 3.07% | -0.4% |
| Volume | 2.46 L | 2.75 L |
| 52-Week High | ₹49.98 | ₹1,193.7 |
| 52-Week Low | ₹30.15 | ₹934.2 |
| Distance from 52W High | -4.48% | -12.99% |
Valuation
| Metric | AMBALALSA | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹307 Cr | ₹6,624 Cr |
| P/E Ratio | 27.1x | — |
| P/B Ratio | 2.22x | — |
| EPS | ₹0.52 | — |
| Book Value | ₹20.67 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | AMBALALSA | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 7,912.25% | — |
| Qtr Profit Growth | 13,108.64% | — |
Profitability & Leverage
| Metric | AMBALALSA | SYMBIOTEC |
|---|---|---|
| ROE | 18.48% | — |
| ROCE | 14.73% | — |
| Net Margin | 8.8% | 0% |
| Operating Margin | 262.56% | — |
| Debt to Equity | 0.19x | — |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AMBALALSA | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 31.36% | 33.28% |
| FII Holding | 0% | 21.08% |
| DII Holding | 0.01% | 27.52% |
| Public Holding | 68.64% | 18.12% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AMBALALSA and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.